drugset / Trial / NCT04816214
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aimed to evaluate the anticancer activity of capmatinib in combination with osimertinib compared to platinum-pemetrexed based doublet chemotherapy as second line treatment in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation, T790M negative, mesenchymal-to-epithelial transition factor (MET) amplified who progressed following EGFR tyrosine kinase inhibitors (TKIs).
Timeline
- Start
- 2021-09-22
- Primary completion
- 2022-12-27
- Completion
- 2022-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capmatinib | Small molecule | 400 mg | Oral |
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Osimertinib | Small molecule | 40 mg | Oral |
| Subject | Osimertinib | Small molecule | 80 mg | Oral |
| Comparator | Pemetrexed | Small molecule | — | Intravenous |